Patterns of Use of the Oncotype DX Breast Recurrence Score® Test in a Kurdish Population of Patients with Breast Cancer: A Multi-Institutional, Retrospective Study

• Hawro T. Hamza

  Department of Oncology, Nanakali Hospital, Azadi street, Erbil, Kurdistan, Iraq.

• Fahmi M. Salih

  Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq.

• Sami S. Omar

  Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq. , Faculty of Medicine, Koya University, Koya, Erbil, Iraq. , Kscien Organization, Hamid Str, Azadi Mall, Sulaimani, Iraq.

• Kalthuma S. Hamadamin

  Department of Pathology, Rizgary Teaching Hospital, Peshawa Qazi Street, Erbil, Kurdistan, Iraq.

• Tara A. Abdulrazzaq

  Department of Oncology, Nanakali Hospital, Azadi street, Erbil, Kurdistan, Iraq.

• Kakil I. Rasul

  Hamad Medical Corporation

Oncotype DX (ODX) is widely used to predict recurrence risk and guide treatment in early-stage, estrogen receptor-positive, HER2-negative breast cancer by analysing 21 genes to provide a recurrence score (RS). Validated in clinical trials, it is endorsed by major organizations like NCCN, ASCO, and ESMO. In the Kurdistan Region of Iraq, ODX is funded by the Cancer Patients' Support Fund (CPSF), but access remains inconsistent. This study aimed to investigate the patterns of Oncotype DX Breast Recurrence Score® test utilization in a Kurdish population of patients with breast cancer, highlighting challenges and opportunities for optimizing patient selection and clinical benefit while addressing financial considerations. This retrospective study in the Kurdistan region of Iraq (2018-2023) involved 300 patients with luminal-type early-stage breast cancer. Data on demographics, tumor characteristics, and Oncotype DX Recurrence Scores® were analyzed to assess test usage patterns. Descriptive statistics were applied, and ethical approval was obtained from all participating centers. The median age of patients was 52 years (range 26-87), with 98.3% being female. Mastectomies were performed in 36% of cases, while 59% had breast-conserving surgeries. Axillary node-positive disease was present in 2.4%, with a median of 6 lymph nodes resected. Most patients had unifocal (76.3%) disease, and invasive ductal carcinoma was the dominant histology (83%). Tumors were primarily grade II (62.9%), with lymphovascular invasion in 17.1% and perineural invasion in 16.1%. Recurrence scores (ORS) were low, intermediate, and high in 16.7%, 54.5%, and 23.4% of cases, respectively. This study provides key insights into breast cancer patients in the Kurdistan region, particularly regarding the use of the Oncotype DX Breast Recurrence Score® test. Most patients were female, with left-sided and invasive ductal carcinoma being more prevalent. The study highlights gaps in sentinel lymph node biopsy implementation and delays in test turnaround times due to healthcare infrastructure challenges.

1 Recommendations | Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | Guidance | NICE. (n.d.). https://www.nice.org.uk/guidance/dg58/chapter/1-Recommendations

Abdou, Y., Gupta, M., Asaoka, M., Attwood, K., Mateusz, O., Gandhi, S., & Takabe, K. (2022). Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Scientific Reports, 12(1), 13377. https://doi.org/10.1038/s41598-022-16749-4

Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., Sledge, G. W., Winer, E. P., Hudis, C., Ingle, J. N., Perez, E. A., Pritchard, K. I., Shepherd, L., Gralow, J. R., Yoshizawa, C., … Hayes, D. F. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology, 11(1), 55–65. https://doi.org/10.1016/S1470-2045(09)70314-6

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., Perou, C. M., Regan, M. M., Rimm, D. L., Symmans, W. F., Torlakovic, E. E., Varella, L., Viale, G., Weisberg, T. F., McShane, L. M., & Wolff, A. C. (2020). Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 38(12), 1346–1366. https://doi.org/10.1200/JCO.19.02309

Amer, M. (2014). Genetic factors and breast cancer laterality. Cancer Management and Research, 191. https://doi.org/10.2147/CMAR.S60006

Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., Litvak, A., Mayer, E. L., Pusztai, L., Raab, R., Wolff, A. C., & Stearns, V. (2022). Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 40(16), 1816–1837. https://doi.org/10.1200/JCO.22.00069

Ashok Kumar, P., Wang, D., Sinha, S., & Sivapiragasam, A. (2019). Does the time to initiate adjuvant chemotherapy effect outcome in patients with breast cancer? A National Cancer Database-based retrospective analysis. Journal of Clinical Oncology, 37(15_suppl), e12054–e12054. https://doi.org/10.1200/JCO.2019.37.15_suppl.e12054

Breast Cancer. (2024). National Comprehensive Cancer Network. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., André, F., Barrios, C., Bergh, J., Bonnefoi, H., Bretel Morales, D., Brucker, S., Burstein, H., Cameron, D., Cardoso, F., … Xu, B. (2021). Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 32(10), 1216–1235. https://doi.org/10.1016/j.annonc.2021.06.023

Cheng, S.-A., Liang, L.-Z., Liang, Q.-L., Huang, Z.-Y., Peng, X.-X., Hong, X.-C., Luo, X.-B., Yuan, G.-L., Zhang, H.-J., & Jiang, L. (2018). Breast cancer laterality and molecular subtype likely share a common risk factor. Cancer Management and Research, Volume 10, 6549–6554. https://doi.org/10.2147/CMAR.S182254

Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., Bowlby, R., Shen, H., Hayat, S., Fieldhouse, R., Lester, S. C., Tse, G. M. K., Factor, R. E., Collins, L. C., Allison, K. H., … Zmuda, E. (2015). Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell, 163(2), 506–519. https://doi.org/10.1016/j.cell.2015.09.033

Desmedt, C., Zoppoli, G., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D., Rothé, F., Vincent, D., Kheddoumi, N., Rouas, G., Majjaj, S., Brohée, S., Van Loo, P., Maisonneuve, P., Salgado, R., Van Brussel, T., Lambrechts, D., … Sotiriou, C. (2016). Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 34(16), 1872–1881. https://doi.org/10.1200/JCO.2015.64.0334

Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., Howell, A., Bugarini, R., Baehner, F. L., & Shak, S. (2010). Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 28(11), 1829–1834. https://doi.org/10.1200/JCO.2009.24.4798

Gagliato, D. de M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H., Valero, V., Hortobagyi, G. N., & Chavez-Macgregor, M. (2014). Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 32(8), 735–744. https://doi.org/10.1200/JCO.2013.49.7693

Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., Leitch, A. M., Saha, S., Hunt, K. K., & Morrow, M. (2017). Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA, 318(10), 918. https://doi.org/10.1001/jama.2017.11470

Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., Dhesy-Thind, S., Rastogi, P., Alba, E., Delaloge, S., Martin, M., Kelly, C. M., Ruiz-Borrego, M., Gil-Gil, M., Arce-Salinas, C. H., … Hortobagyi, G. N. (2021a). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 385(25), 2336–2347. https://doi.org/10.1056/NEJMoa2108873

Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., Dhesy-Thind, S., Rastogi, P., Alba, E., Delaloge, S., Martin, M., Kelly, C. M., Ruiz-Borrego, M., Gil-Gil, M., Arce-Salinas, C. H., … Hortobagyi, G. N. (2021b). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 385(25), 2336–2347. https://doi.org/10.1056/NEJMoa2108873

Kim, C., Tang, G., Pogue-Geile, K. L., Costantino, J. P., Baehner, F. L., Baker, J., Cronin, M. T., Watson, D., Shak, S., Bohn, O. L., Fumagalli, D., Taniyama, Y., Lee, A., Reilly, M. L., Vogel, V. G., McCaskill-Stevens, W., Ford, L. G., Geyer, C. E., Wickerham, D. L., … Paik, S. (2011). Estrogen Receptor ( ESR1 ) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 29(31), 4160–4167. https://doi.org/10.1200/JCO.2010.32.9615

Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., Ashikaga, T., Weaver, D. L., Mamounas, E. P., Jalovec, L. M., Frazier, T. G., Noyes, R. D., Robidoux, A., Scarth, H. M., & Wolmark, N. (2010). Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology, 11(10), 927–933. https://doi.org/10.1016/S1470-2045(10)70207-2

Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., … Harbeck, N. (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 35(2), 159–182. https://doi.org/10.1016/j.annonc.2023.11.016

Lyman, G. H., Somerfield, M. R., Bosserman, L. D., Perkins, C. L., Weaver, D. L., & Giuliano, A. E. (2017). Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 35(5), 561–564. https://doi.org/10.1200/JCO.2016.71.0947

Matikas, A., Foukakis, T., Swain, S., & Bergh, J. (2019). Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Annals of Oncology, 30(7), 1044–1050. https://doi.org/10.1093/annonc/mdz126

Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., & Wolmark, N. (2004). A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine, 351(27), 2817–2826. https://doi.org/10.1056/NEJMoa041588

Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., Costantino, J. P., Geyer, C. E., Wickerham, D. L., & Wolmark, N. (2006). Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 24(23), 3726–3734. https://doi.org/10.1200/JCO.2005.04.7985

Penault-Llorca, F., & Radosevic-Robin, N. (2017). Ki67 assessment in breast cancer: an update. Pathology, 49(2), 166–171. https://doi.org/10.1016/j.pathol.2016.11.006

Perkins, C. I., Hotes, J., Kohler, B. A., & Howe, H. L. (2004). Association between Breast Cancer Laterality and Tumor Location, United States, 1994–1998. Cancer Causes & Control, 15(7), 637–645. https://doi.org/10.1023/B:CACO.0000036171.44162.5f

Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., Palacios, J., Richardson, A. L., Schnitt, S. J., Schmitt, F. C., Tan, P.-H., Tse, G. M., Badve, S., & Ellis, I. O. (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research, 12(4), 207. https://doi.org/10.1186/bcr2607

Reis-Filho, J. S., & Pusztai, L. (2011). Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet, 378(9805), 1812–1823. https://doi.org/10.1016/S0140-6736(11)61539-0

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., … Sledge, G. W. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 379(2), 111–121. https://doi.org/10.1056/NEJMoa1804710

Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., McShane, L. M., Saphner, T. J., Spears, P. A., & Allison, K. H. (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology, 41(22), 3867–3872. https://doi.org/10.1200/JCO.22.02864

Zhang, F., Chen, H., Luo, D., Xiong, Z., Li, X., Yin, S., Jin, L., Chen, S., Peng, J., & Lian, L. (2023). Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer. Cancer Medicine, 12(8), 9401–9408. https://doi.org/10.1002/cam4.5701

Zhu, X., Dent, S., Paquet, L., Zhang, T., Tesolin, D., Graham, N., Aseyev, O., & Song, X. (2021). How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients. Current Oncology, 28(1), 800–812. https://doi.org/10.3390/curroncol28010077

• HTML
• PDF

• Assessment Tools in Oncology

Copyright (c) 2025 Hawro T. Hamza, Fahmi M. Salih, Sami S. Omar, Kalthuma S. Hamadamin, Tara A. Abdulrazzaq, Kakil I. Rasul

This work is licensed under a Creative Commons Attribution 4.0 International License.